Strategic Insight reports are designed to support strategic objectives and planning by Integrated Care System (ICS) leaders. Through the analysis of data and communication with key stakeholders across the ICS, interventions to be undertaken by the ICS are proposed to Integrated Care Boards or associated committees.
This report highlights the benefits of electronic repeat dispensing (eRD) and examines its use at ICS level in the North of England, in order to support systems in identifying where prescribing processes may be further streamlined.
This report looks at the top 50 BNF sections and drugs in terms of spend at CCG level for the financial year to date with a focus on cost growth and item growth.
April 2021 to March 2022
The charts included within this report are organised by BNF classification (legacy) and show comparative costs at the NHS basic price1,2 (as of July 2022) for selected agents. Except where indicated otherwise, each chart shows the cost of 1 year3 of treatment at a commonly prescribed daily dose (shown in brackets). The doses given are not intended to imply therapeutic equivalence and for some BNF sub-classifications, such as angiotensin converting enzyme inhibitors (ACE inhibitors), the doses may vary according to indication. Additionally, in some therapeutic areas, for instance antibacterial drugs, the duration of treatment may differ from that shown. Primarily, this report focuses on costs related to prescribing in adults. There are however a few exceptions where products specifically for use in children are represented, such as in the emollient and Infant formulas sections. Additional notes to highlight any relevant cost related information are also added where appropriate, to improve the clarity of the information presented.
Rationale for inclusion: the cost comparison charts (CCCs) aim to represent the diversity of products available; including the least expensive, most prescribed, higher cost products being prescribed and products with additional features. The products included are furthermore considered in the context of national and local guidance and stakeholder formulary decisions. It is not possible to represent all pharmaceuticals within these charts.
Stakeholders (under password protection) can access the current version of the CCCs via our website in three formats: PDF, Word and Excel. The Excel version incorporates a more detailed comparison of contraceptives and allows charts to be split by BNF subsections in some instances.
3. 1 year in this instance is equal to 364 days (rather than 365) standardising 1 month as equal to 28 days.
This bulletin provides an update on key primary care prescribing trends in the North of England, which relate to ‘Overprescribing’; incorporating ‘Polypharmacy’. It provides a snapshot of overprescribing in the North of England Integrated Care Systems, including the percentage of patients receiving five or more unique analgesic medicines, and those receiving three unique medicines (not licensed for hypertension) with a hypotensive side effect.
A supplementary appendices containing the respective CCG level data is also available to download
Monthly horizon scanning reports are designed to inform the NHS about new products, significant changes to product licenses, significant new guidance, and decisions that have been made by recognised bodies
This information is produced for use by NHS healthcare professionals.